Study to Evaluate Imaging Response Using 177LuLu-PSMA in Men with Advanced Metastatic Castration-Resistant Prostate Cancer
Led by University Hospital, Grenoble · Updated on 2025-12-26
130
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of Lutetium-177 177Lu prostate-specific membrane antigen PSMA imaging to evaluate treatment response in patients with metastatic castration-resistant prostate cancer mCRPC. This study focuses on the potential of LuPSMA-SPECTCT, a cost-effective imaging method, to serve as an early marker for assessing response to 177Lu-PSMA therapy, which has been approved for late-stage PSMA-positive mCRPC. The study aims to improve early treatment decisions and patient care by detecting tumor progression sooner.
Participants will receive 177Lu-PSMA therapy and undergo serial LuPSMA-SPECTCT imaging after each treatment dose. The study will also assess interim PSMA-PETCT scans performed 10 weeks after treatment initiation. Researchers will compare the cost-effectiveness and clinical impact of SPECTCT versus PETCT imaging methods and explore additional PET imaging with 18FFDG to evaluate response. The study spans from treatment start to at least 12 months after treatment initiation.
During the study, participants will have imaging scans, including LuPSMA-SPECTCT and PSMA-PETCT, to monitor tumor response and progression. Researchers will analyze tumor burden and imaging parameters to confirm the prognostic value of these imaging techniques for overall survival and progression-free survival. The study also evaluates agreement between image readers to ensure consistency. Participant involvement includes regular imaging and clinical assessments over the course of a year or longer.
CONDITIONS
Brief Title
Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer
Research Team
L
Loïc DJAÏLEB, PU-PH
M
Marine FAURE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adult aged 18 or older with proven adenocarcinoma of the prostate
Diagnosis of progressive metastatic castration-resistant prostate cancer
Progression or intolerance on a novel anti-androgen therapy such as abiraterone, enzalutamide, apalutamide, or darolutamide
Prior therapy with at least one taxane-based chemotherapy or patient symptomatic and unfit for chemotherapy
Eastern Cooperative Oncology Group (ECOG) Performance status 0 to 2
You will not qualify if you...
Patient opposed to the use of his data for clinical research
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - From treatment initiation to at least 12 months after treatment initiation
Participants undergo imaging assessments to evaluate response biomarkers during treatment.
Multiple imaging visits including SPECT/CT and PET/CT scans
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Study of New Hormone Therapy Combined With Local Treatment Using PSMA PETCT in Men With Metastatic Hormone-Sensitive Prostate Cancer
Stereotactic Radiotherapy for Treating Bone and Lymph Node Metastases in Advanced Therapy-Resistant Prostate Cancer
Studying Lab-Grown Mini-Tumors From Prostate Cancer Tissue to Predict Best Treatment
Using Patient-Derived 3D Cultures for Men With High-Risk or Metastatic Prostate Cancer
Trial to Evaluate Fezolinetant for Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Study to Evaluate Imaging Response Using 177LuLu-PSMA in Men with Advanced Metastatic Castration-Resistant Prostate Cancer
Study of PSMA PET Scan Added to MRI for Monitoring Prostate Cancer After Partial Gland Ablation
Phase II Study of Radiotherapy or Radical Prostatectomy with Intense Androgen Deprivation Therapy for Newly Diagnosed Metastatic Prostate Cancer in Men
Nutritional Strategies to Reduce Cardiovascular Risks in African American and Non-Hispanic White Men on Androgen Deprivation Therapy for Metastatic Prostate Cancer
Study of OTL78, a PSMA-targeted Fluorescent Agent, for Imaging Prostate Cancer During Surgery to Assess Safety and Effectiveness
Using FAPI PETMRI Scans to Improve Diagnosis and Monitoring of Prostate Cancer in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Qaid Ahmed Shagera, Ioannis Karfis, Paulus Kristanto...
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.